Monday, August 30, 2021

Monoclonal antibody treatment combo reduces hospitalization among high-risk patients with COVID-19

In an observational study, researchers report that the combination of casirivimab and imdevimab -- two monoclonal antibody treatments under Food and Drug Administration emergency use authorization -- keep high-risk patients out of the hospital when infected with mild to moderate COVID-19.

from Latest Science News -- ScienceDaily https://ift.tt/3gILcnA
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Study finds untreated sleep apnea doubles Parkinson’s risk

A massive veteran study found a strong connection between untreated sleep apnea and a higher chance of Parkinson’s. CPAP users had much lowe...